Compare Boston Scientific Corporation (BSX) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Remitly Global Inc — how do they compare? Boston Scientific Corporation trades at $42.73 (market cap $66.37B), while Remitly Global Inc trades at $23.24 (market cap $4.98B). The key difference: Boston Scientific Corporation is far larger — about 13.3× Remitly Global Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | RELY | |
|---|---|---|
Market Cap | $66.37B | $4.98B |
Sector | Health | Technology |
52-Week High | $108.14 | $24.28 |
52-Week Low | $42.63 | $12.20 |
Enterprise Value | $75.94B | $4.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
RELY trades at $23.68, down 0.38% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates accelerating revenue growth, reaching $1.64B in 2025 with net income turning positive at $67.93M. Recent expansion includes a UAE banking license and Canadian business launch, supporting the 92% analyst buy rating with a $26.75 consensus target.
Outlook remains positive with projected 2026 revenue of $1.7B and net income of $106M. Key opportunities include market share gains in the $800B remittance space, while risks involve competitive pressure from payment giants and execution challenges in international expansion. The stock offers growth potential but requires monitoring of profitability sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
